Roopal Thakkar - Dec 14, 2023 Form 3 Insider Report for AbbVie Inc. (ABBV)

Role: SVP, Global Therapeutics & CMO
Signature: T.O. Odutayo, Attorney-in-Fact for Roopal Thakkar
Stock symbol: ABBV
Transactions as of: Dec 14, 2023
Transactions value $: $0
Form type: 3
Date filed: 12/22/2023, 04:13 PM
Next filing: Feb 20, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	ABBV	Common Stock, $0.01 par value						30.2K	Dec 14, 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	ABBV	Option (Right to buy)							Dec 14, 2023	Common Stock	18K	$93.50	Direct	F2
holding	ABBV	Option (Right to buy)							Dec 14, 2023	Common Stock	7.76K	$105.92	Direct	F3
holding	ABBV	Option (Right to buy)							Dec 14, 2023	Common Stock	7.01K	$144.54	Direct	F4
holding	ABBV	Option (Right to buy)							Dec 14, 2023	Common Stock	8.1K	$149.62	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 6,918 restricted stock units granted under the AbbVie Amended and Restated 2013 Incentive Stock Program. These restricted stock units vest in full on February 17, 2025, and include the right to have stock withheld for tax purposes.
F2	Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 6,001 shares on 02/20/2021, as to 6,001 shares on 02/20/2022, and as to 6,001 shares on 02/20/2023.
F3	Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 2,588 shares on 02/18/2022 and as to 2,588 shares on 02/18/2023, and will become exercisable as to as to 2,587 shares on 02/18/2024.
F4	Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 2,335 shares on 02/17/2023, and will become exercisable as to 2,335 shares on 02/17/2024 and as to 2,335 shares on 02/17/2025.
F5	Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option will become exercisable as to 2,701 shares on 02/16/2024, as to 2,701 shares on 02/16/2025 and as to 2,700 shares on 02/16/2026.